C4 Therapeutics (CCCC) News Today $4.31 -0.41 (-8.69%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Large Drop in Short InterestC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large decrease in short interest in October. As of October 31st, there was short interest totalling 5,850,000 shares, a decrease of 12.0% from the October 15th total of 6,650,000 shares. Based on an average trading volume of 975,000 shares, the days-to-cover ratio is currently 6.0 days.November 16 at 6:55 PM | marketbeat.comC4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical TrialNovember 7, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for C4 Therapeutics (CCCC)November 7, 2024 | markets.businessinsider.comMorgan Stanley Keeps Their Hold Rating on C4 Therapeutics (CCCC)November 5, 2024 | markets.businessinsider.comC4 Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 2, 2024 | finance.yahoo.comC4 Therapeutics Advances in Protein Degradation TherapyNovember 1, 2024 | markets.businessinsider.comC4 Therapeutics files $400M mixed securities shelfOctober 31, 2024 | markets.businessinsider.comC4 Therapeutics files to sell 4.87M shares of common stock for holdersOctober 31, 2024 | markets.businessinsider.comC4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsOctober 31, 2024 | markets.businessinsider.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Moderate Buy" by BrokeragesC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have given a buOctober 31, 2024 | marketbeat.comWe're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash WiselyOctober 29, 2024 | finance.yahoo.comC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 28, 2024 | globenewswire.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest UpdateC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 6,650,000 shares, a decline of 39.6% from the September 30th total of 11,010,000 shares. Based on an average trading volume of 988,500 shares, the days-to-cover ratio is currently 6.7 days.October 26, 2024 | marketbeat.comC4 Therapeutics, Inc.: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.October 17, 2024 | finanznachrichten.deC4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.October 15, 2024 | globenewswire.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Shares Sold by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC lowered its position in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 26.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 560,959 shares of the company's stockOctober 12, 2024 | marketbeat.comC4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity SummitOctober 9, 2024 | globenewswire.comRenaissance Technologies LLC Sells 170,600 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)Renaissance Technologies LLC cut its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 42.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 235,200 shares of the company's stock afterOctober 7, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Hold" from BrokeragesShares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have been given a consensus recommendation of "Hold" by the seven brokerages that are covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold rating and three have issued a buy rating on the comOctober 6, 2024 | marketbeat.comPoint72 Asset Management L.P. Sells 627,892 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)Point72 Asset Management L.P. reduced its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 69.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 278,580 shares of the company's stock after seOctober 4, 2024 | marketbeat.comC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 30, 2024 | globenewswire.comC4 Therapeutics, Inc. (NASDAQ:CCCC) is Lynx1 Capital Management LP's 4th Largest PositionLynx1 Capital Management LP lifted its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 89.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,880,527 shares of the company's stock after buying anSeptember 27, 2024 | marketbeat.comBank of New York Mellon Corp Takes Position in C4 Therapeutics, Inc. (NASDAQ:CCCC)Bank of New York Mellon Corp acquired a new position in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 190,761 shares of the company's stock, valued at approximately $881,000. Bank of NeSeptember 22, 2024 | marketbeat.comCCCC Oct 2024 12.000 callSeptember 21, 2024 | ca.finance.yahoo.comAcadian Asset Management LLC Buys 91,443 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)Acadian Asset Management LLC increased its stake in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 415.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 113,436 shares of the company's stock after acquiSeptember 19, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Growth in Short InterestC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 11,630,000 shares, an increase of 10.8% from the August 15th total of 10,500,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is currently 7.4 days.September 17, 2024 | marketbeat.comCautious Hold Rating on C4 Therapeutics Amid Modest Efficacy and Pending DataSeptember 16, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on C4 Therapeutics (CCCC)September 16, 2024 | markets.businessinsider.comHold Rating on C4 Therapeutics Amid Early-Stage Drug Development and Market CautionSeptember 15, 2024 | markets.businessinsider.comC4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024September 13, 2024 | globenewswire.comBMO maintains Outperform rating on C4 Therapeutics stockSeptember 11, 2024 | uk.investing.comAnalyst maintains Buy on C4 Therapeutics shares, notes early signs of BRAF degrader efficacySeptember 11, 2024 | uk.investing.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of "Hold" by BrokeragesC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has received an average recommendation of "Hold" from the seven analysts that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to tSeptember 11, 2024 | marketbeat.comC4 Therapeutics, Inc.: C4 Therapeutics Announces Delivery of Second Development Candidate to BiogenSeptember 10, 2024 | finanznachrichten.deC4 Therapeutics Announces Delivery of Second Development Candidate to BiogenSeptember 10, 2024 | markets.businessinsider.comC4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024September 8, 2024 | globenewswire.comC4 Therapeutics (CCCC) Gets a Buy from Stifel NicolausSeptember 5, 2024 | markets.businessinsider.comC4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of DirectorsSeptember 3, 2024 | globenewswire.comC4 Therapeutics to Participate in Upcoming September Investor ConferencesAugust 29, 2024 | globenewswire.comC4 Therapeutics Target of Unusually High Options Trading (NASDAQ:CCCC)C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors purchased 10,243 put options on the company. This is an increase of approximately 2,146% compared to the average volume of 456 put options.August 27, 2024 | marketbeat.comHennion & Walsh Asset Management Inc. Makes New Investment in C4 Therapeutics, Inc. (NASDAQ:CCCC)Hennion & Walsh Asset Management Inc. bought a new position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 142,832 shares of the company's stoAugust 21, 2024 | marketbeat.comShort Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Decreases By 10.0%C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 10,470,000 shares, a decrease of 10.0% from the July 15th total of 11,630,000 shares. Based on an average trading volume of 1,660,000 shares, the days-to-cover ratio is presently 6.3 days.August 18, 2024 | marketbeat.comVanguard Group Inc. Increases Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC)Vanguard Group Inc. increased its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 46.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,920,028 shares of the company's stock after purchAugust 11, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and C4 Therapeutics (CCCC)August 6, 2024 | markets.businessinsider.comBuy Rating on C4 Therapeutics: Key Clinical Milestones and Drug Candidate PotentialAugust 6, 2024 | markets.businessinsider.comC4 Therapeutics' (CCCC) Outperform Rating Reaffirmed at BMO Capital MarketsBMO Capital Markets reaffirmed an "outperform" rating and set a $20.00 target price on shares of C4 Therapeutics in a research note on Tuesday.August 6, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Stake Lessened by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD lowered its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 17.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,115,477 shares of the company's stAugust 3, 2024 | marketbeat.comC4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 1, 2024 | globenewswire.comAcadian Asset Management LLC Has $179,000 Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC)Acadian Asset Management LLC reduced its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 87.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,993 shares of the company's stock afterJuly 29, 2024 | marketbeat.comShort Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Increases By 32.0%C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 11,630,000 shares, an increase of 32.0% from the June 30th total of 8,810,000 shares. Based on an average daily volume of 1,670,000 shares, the short-interest ratio is presently 7.0 days.July 27, 2024 | marketbeat.com Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address How one pattern has averaged an 85% return per year since the pandemic. (Ad)Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern… Follow this link here and enter your email address to sign up… CCCC Media Mentions By Week CCCC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CCCC News Sentiment▼1.440.55▲Average Medical News Sentiment CCCC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CCCC Articles This Week▼33▲CCCC Articles Average Week Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alector News Today Inhibrx News Today Compugen News Today Ocular Therapeutix News Today Kiniksa Pharmaceuticals News Today Day One Biopharmaceuticals News Today ARS Pharmaceuticals News Today Xencor News Today Arcus Biosciences News Today Intellia Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CCCC) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
